Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Stereotaxis raises $20.1 mil.: Firm tabs $20.1 million in net proceeds from a private placement stock offering for marketing, R&D and working capital. The offering includes approximately 1.9 million common stock shares at $10.50 each. Stereotaxis, which makes magnetic interventional navigation systems for cardiac catheterization labs, generated revenue of $27.2 million in 2006 - an 81% jump from the prior year. A net loss for the year of $45.7 million compares to a loss of $43.6 million a year earlier. As of year-end 2006, the firm had $37 million in cash on hand. On March 1, the firm announced the start of its HEAL HF trial to evaluate its Niobe system for magnetic navigation to multiple potential pacing sites and optimization of left ventricular lead placement to treat heart failure. Stereotaxis went public in 2004 (1"The Gray Sheet" Sept. 27, 2004, p. 12)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel